Amgen Inc. (AMGN) Stock Research, Analysis & News

Quick Analysis on Amgen Inc. (AMGN) Stock as of November 24, 2017

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Amgen Inc. (AMGN) Stock below)

Amgen Inc. (AMGN) Stock Profile Summary

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the bodys response to inflammatory diseases. The company also markets other products, including Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a human monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, its lead product in mid-to-late stage development include Denosumab, a human monoclonal antibody that targets a ligand, known as RANKL, an essential regulator of osteoclasts, which is under regulatory review. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc. (AMGN) Stock Key Statistics Research and Analysis as of November 24, 2017

Amgen Inc. (AMGN) Stock Competitor Research and Analysis

Johnson & Johnson (JNJ)Novartis AG (NVS)
Sanofi-Aventis (SNY)Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
GlaxoSmithKline plc (GSK)

Mutual Funds with Amgen Inc. (AMGN) Stock in its top 10 holdings

FundCategoryAMGN Holding Percentage
American Century Disciplined Growth CLarge Growth1.97%
American Funds Growth Fund of Amer BLarge Growth1.74%
American Funds Invmt Co of Amer BLarge Blend4.82%

ETFs with Amgen Inc. (AMGN) Stock in its top 10 holdings

Stock Research on Amgen Inc. (AMGN)

Latest Market News on Amgen Inc. (AMGN)


Click here to find the latest news on Amgen Inc. (AMGN)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Johnson & Johnson (JNJ)
Novartis AG (NVS)
Sanofi-Aventis (SNY)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
GlaxoSmithKline plc (GSK)